Maze Therapeutics (MAZE) Free Cash Flow (2024 - 2026)

Maze Therapeutics has reported Free Cash Flow for 3 years, with the latest figure at -$39.2 million in Q1 2026.

• Quarterly Free Cash Flow fell 31.5% year-over-year to -$39.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$122.1 million (down 277.74% YoY) and the FY2025 annual result came in at -$112.7 million, down 250.7% from the prior year.
• Free Cash Flow eased to -$39.2 million in Q1 2026 per MAZE's latest filing, from -$28.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $145.3 million in Q2 2024 and troughed at -$39.2 million in Q1 2026.
• A 3-year average of -$8.6 million and a median of -$24.0 million in 2025 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 2.58% in 2025, down 120.95% in 2025.
• Over 3 years, Free Cash Flow stood at -$23.4 million in 2024, then declined by 21.8% to -$28.5 million in 2025, then tumbled by 37.61% to -$39.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$39.2 million, -$28.5 million, and -$24.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.